Dr. Dhanoa

Biography

Dr. Dhanoa is the CEO of Akaal Pharma. Previously he was the Managing Director and Chairman of the Scientific Advisory Board of Akaal Pharma. Dr. Dhanoa has nearly 20 years of experience in management and directing research and development in drug discovery and development with a proven track record of success. He is a co-inventor and co-author of over 100 patents and publications. He has held positions of increasing responsibilities at Merck, Synaptic Pharmaceuticals, Alanex Corporation, 3-Dimensional Pharmaceuticals, Pharmacore and Predix Pharmaceuticals. He was the founding Senior Vice President of R&D at Predix Pharmaceuticals, and later Senior Vice President of Drug Discovery at Predix Pharmaceuticals Holding Company after M&A of Predix with Physiome Sciences. He was the Executive Vice President and Chief Scientific Officer at PharmaCore, Executive Director of Drug Discovery at 3-Dimensional Pharmaceuticals (dddp/nasdaq, acquired by Johnson & Johnson), Director of Chemistry at Alanex (acquired by Agouron, now Pfizer), Associate Director of Medicinal Chemistry at Synaptic Pharmaceuticals (snap/nasdaq, acquired by H. Lundbeck A/S). Under Dr. Dhanoa’s R&D direction and management at Predix Pharmaceuticals, several new small molecule drug candidates were discovered in an unprecedented short period of less than three years. Four of these novel clinical product candidates advanced through Phase I, II and III clinical trials. PRX-03140, a novel drug candidate for the treatment of Alzheimer’s Disease, was partnered with GlaxoSmithKline(GSK) for $1.2 Billion. The pipeline of new and innovative drug candidates created by Dr. Dhanoa and his team at Predix resulted in raising significant venture capital prior to its M&A with Epix Pharma (epix/nasdaq).

Research Interest

Pharma, Clinical research, Pharmaceutical sciences